Key Takeaways
- • Varonis agreed to be acquired by Thoma Bravo-backed Proofpoint for a $6.3 billion takeover at $49.75 per share, after its board had initially sought $54 per share, according to a preliminary proxy statement dated Nov 5.
- • None of the eight strategic buyers approached by Goldman Sachs made an offer, and the only rival private equity bid of $38 to $40 per share was rejected as inadequate.
- • The headline premium is 52% over the Jun 22 close of $32.71, the last day before sale rumors, though the price remains below the roughly $63 level before the October 2025 share plunge.
- • Thoma Bravo's reverse termination fee is 6.75%, or $423.3 million, exactly twice the $211.7 million superior-bid fee Varonis would owe, per the filing.
- • The deal is expected to close in the first half of 2027, pending a US antitrust waiting period expiring Nov 18 and a Varonis shareholder vote.
Summary
A newly filed preliminary proxy statement dated Nov 5 gives the most detailed account yet of how Israeli-founded cybersecurity company Varonis came to be sold to Thoma Bravo for $6.3 billion, with the deal structured as a takeover by Proofpoint, a Thoma Bravo portfolio company. According to the filing, Varonis's board initially asked for $54 per share in August and accepted $49.75 after Thoma Bravo described its offer as "best and final."
The process began after a sharp decline in the stock. Shares fell about 49% in one session on Oct 29, 2025, following weak results and a staff cut announced without a profit warning, and hit an intraday low of $19.70 on April 10. By April 27, the board cited macroeconomic uncertainty, potential disruption from artificial intelligence models, and "credible inbound interest from Thoma Bravo" as reasons to explore a sale. A four-member transaction committee was formed and Goldman Sachs was authorized on May 4 to approach eight strategic parties. None of them is described as making an offer. Proofpoint's initial non-binding proposal of $36 per share, about a 28% premium to the prior close, was judged by the committee as insufficient in price and certainty. By July 20, only one strategic buyer remained, showing limited interest.
Four financial sponsors approached the company independently. Sponsor D indicated $38 to $40 per share after meeting Varonis executives in August, but the board rejected it as not reflecting the company's intrinsic value. Another sponsor's interest was in the low-to-mid $30s and it did not bid.
Thoma Bravo raised its bid in steps: $43 verbally on Aug 11, $46.50 in writing on Aug 13, and $49.50 on Aug 17. After the board authorized a $50 counter on Aug 18, Thoma Bravo returned with $49.75. The board declined to re-engage other bidders. Signing took until Oct 15, with much of the negotiation focused on termination fees. The superior-bid fee settled at 3.375%, while Thoma Bravo's reverse fee ended at 6.75%. Thoma Bravo's requests for expense reimbursement and director voting agreements were refused, and only CEO Yaki Faitelson signed a voting agreement, covering about 0.67% of shares.
Valuation metrics vary by reference date. The headline premium is 52% against the Jun 22 close, 17.5% against the Sep 1 close used in Goldman's fairness analysis, and 2.1% against the Oct 13 close of $48.72. Goldman's discounted cash flow analysis produced a range of $36.40 to $54.12 per share, with the deal price in the upper half. Goldman, Varonis's adviser, expects about $63 million in fees if the deal closes and disclosed roughly $227 million in compensation from Thoma Bravo over the past two years, along with a lending relationship with the firm.
For executives, the proxy estimates merger-related payments of about $106 million for Faitelson, most of it performance share units, and roughly $39.8 million and $39.7 million for CFO Guy Melamed and CTO David Bass. Faitelson will serve for 18 months after closing at a $560,000 salary and $440,000 target bonus, plus units with a $10 million target value, and has agreed to reinvest $15 million of his proceeds. The merger agreement requires Proofpoint to maintain pay and benefits in aggregate until the earlier of Dec 31, 2027 or 12 months after closing, with no headcount commitment. Varonis employs about 2,800 people, roughly 1,000 of them in Herzliya, Israel.
The US antitrust waiting period expires Nov 18, with additional filings required in Australia, France, Italy, Luxembourg and the UK. The shareholder meeting date has not yet been set, and the companies expect to close in the first half of 2027.
The process began after a sharp decline in the stock. Shares fell about 49% in one session on Oct 29, 2025, following weak results and a staff cut announced without a profit warning, and hit an intraday low of $19.70 on April 10. By April 27, the board cited macroeconomic uncertainty, potential disruption from artificial intelligence models, and "credible inbound interest from Thoma Bravo" as reasons to explore a sale. A four-member transaction committee was formed and Goldman Sachs was authorized on May 4 to approach eight strategic parties. None of them is described as making an offer. Proofpoint's initial non-binding proposal of $36 per share, about a 28% premium to the prior close, was judged by the committee as insufficient in price and certainty. By July 20, only one strategic buyer remained, showing limited interest.
Four financial sponsors approached the company independently. Sponsor D indicated $38 to $40 per share after meeting Varonis executives in August, but the board rejected it as not reflecting the company's intrinsic value. Another sponsor's interest was in the low-to-mid $30s and it did not bid.
Thoma Bravo raised its bid in steps: $43 verbally on Aug 11, $46.50 in writing on Aug 13, and $49.50 on Aug 17. After the board authorized a $50 counter on Aug 18, Thoma Bravo returned with $49.75. The board declined to re-engage other bidders. Signing took until Oct 15, with much of the negotiation focused on termination fees. The superior-bid fee settled at 3.375%, while Thoma Bravo's reverse fee ended at 6.75%. Thoma Bravo's requests for expense reimbursement and director voting agreements were refused, and only CEO Yaki Faitelson signed a voting agreement, covering about 0.67% of shares.
Valuation metrics vary by reference date. The headline premium is 52% against the Jun 22 close, 17.5% against the Sep 1 close used in Goldman's fairness analysis, and 2.1% against the Oct 13 close of $48.72. Goldman's discounted cash flow analysis produced a range of $36.40 to $54.12 per share, with the deal price in the upper half. Goldman, Varonis's adviser, expects about $63 million in fees if the deal closes and disclosed roughly $227 million in compensation from Thoma Bravo over the past two years, along with a lending relationship with the firm.
For executives, the proxy estimates merger-related payments of about $106 million for Faitelson, most of it performance share units, and roughly $39.8 million and $39.7 million for CFO Guy Melamed and CTO David Bass. Faitelson will serve for 18 months after closing at a $560,000 salary and $440,000 target bonus, plus units with a $10 million target value, and has agreed to reinvest $15 million of his proceeds. The merger agreement requires Proofpoint to maintain pay and benefits in aggregate until the earlier of Dec 31, 2027 or 12 months after closing, with no headcount commitment. Varonis employs about 2,800 people, roughly 1,000 of them in Herzliya, Israel.
The US antitrust waiting period expires Nov 18, with additional filings required in Australia, France, Italy, Luxembourg and the UK. The shareholder meeting date has not yet been set, and the companies expect to close in the first half of 2027.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.